Correction of morphofunctional disorders of the cardiovascular system with asialized erythropoietin and arginase II selective inhibitors KUD 974 and KUD 259 in experimental preeclampsia

Authors

DOI:

https://doi.org/10.3897/rrpharmacology.6.50851

Abstract

Introduction: Preeclampsia remains one of the most common causes of maternal and perinatal mortality worldwide. A significant role in the pathogenesis of this pathology is assigned to placental ischemia and endothelial dysfunction. Therefore, the aim of the present study was to study the effectiveness of asialized erythropoietin and arginase II selec­tive inhibitors: KUD-259 and KUD-974 in the correction of morphofunctional disorders of the cardiovascular system in experimental preeclampsia.

Materials and methods: The study was performed in 260 female Wistar rats, each weighing 250–300 g. An AD­MA-like preeclampsia was reproduced in the experiment. To assess the emerging morphofunctional disorders, the fol­lowing parameters were used: blood pressure, coefficient of endothelial dysfunction, microcirculation in the placenta, proteinuria, fluid content in the omentum, concentration of terminal metabolites in the blood plasma, and morphometric parameters of fetuses.

Results and discussion: The administration of arginase II selective inhibitor KUD-974 in combination with asialized erythropoietin leads to a pronounced correction of emerging changes: a decrease in systolic and diastolic blood pres­sure in 1.5 and 1.7 times, a decrease in proteinuria in 3.6 times and a decrease in fluid content in the omentum. When arginase II selective inhibitor KUD 974 and asialized erythropoietin are used with methyldopa, the positive effects of the former are enhanced.

Conclusion: Arginase II selective inhibitors KUD-259 and KUD-974 and asialized erythropoietin have a pronounced positive effect on the correction of morphofunctional disorders in animals with ADMA-like preeclampsia.

Keywords:

arginase II selective inhibitor, asialized erythropoietin, preeclampsia, endothelial dysfunction

Author Contribution

Tatyana I. Lokteva, Belgorod State University

Postgraduate student, Department of Pharmacology and Clinical Pharmacology.

Il’ya S. Rozhkov, Belgorod State University

Postgraduate student, Department of Pharmacology and Clinical Pharmacology.

Vladimir V. Gureev, Belgorod State University

Doctor of Medical Sciences, Associate Professor, Professor of the Department of Pharmacology and Clinical Pharmacology.

Anastasia V. Gureeva, Kursk State Medical University

3-year student, Faculty of Medicine.

Marija A. Zatolokina, Kursk State Medical University

Doctor of Medical Sciences, Assistant Professor, Professor of the Department of Histology, Embryology, Cytology.

Elena V. Avdeeva, Kursk State Medical University

Doctor of Biological Sciences, Professor of the Department of Normal Physiology.

Lyudmila A. Zhilinkova, Kursk Academy of State and Municipal Service

PhD in Technical Sciences, Associate Professor, Department of Philosophy, Social, Legal and Natural Sciences.

Evgenij E. Prohoda, Kursk Regional Clinical Hospital

Medical doctor of the Kursk Regional Clinical Hospital.

Elizoveta O. Yarceva, Kursk State Medical University

6-year student, Faculty of Medicine.

Downloads

Published

20-03-2020

How to Cite

Lokteva TI, Rozhkov IS, Gureev VV, Gureeva AV, Zatolokina MA, Avdeeva EV, Zhilinkova LA, Prohoda EE, Yarceva EO (2020) Correction of morphofunctional disorders of the cardiovascular system with asialized erythropoietin and arginase II selective inhibitors KUD 974 and KUD 259 in experimental preeclampsia. Research Results in Pharmacology 6(1): 29–40. https://doi.org/10.3897/rrpharmacology.6.50851

Issue

Section

Review article

Most read articles by the same author(s)